These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 26080292

  • 1. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
    Farinde A.
    Nurse Pract; 2015 Jul 15; 40(7):16-7. PubMed ID: 26080292
    [No Abstract] [Full Text] [Related]

  • 2. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F.
    Rev Med Liege; 2013 Sep 15; 68(9):486-8. PubMed ID: 24180205
    [Abstract] [Full Text] [Related]

  • 3. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E, Marcos C, Alonso T, Giron RM, Gomez-Punter RM, Garcia-Castillo E, Zamora E, Cisneros C, Garcia J, Valenzuela C, Ancochea J.
    Expert Rev Anti Infect Ther; 2016 Sep 15; 14(1):9-17. PubMed ID: 26559549
    [Abstract] [Full Text] [Related]

  • 4. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun 24; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract] [Full Text] [Related]

  • 5. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM, Waugh J, Noble S.
    Drugs; 2003 Jun 24; 63(22):2501-20. PubMed ID: 14609360
    [Abstract] [Full Text] [Related]

  • 6. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F, Carnovale V, Cimino G, Lucidi V, Salvatore D, Messore B, Bartezaghi M, Muscianisi E, Porpiglia PA, FREE study group.
    Respir Med; 2018 May 24; 138():88-94. PubMed ID: 29724399
    [Abstract] [Full Text] [Related]

  • 7. Inhaled tobramycin (TOBI).
    Bonsignore CL.
    Pediatr Nurs; 1998 May 24; 24(3):258-9. PubMed ID: 9987427
    [Abstract] [Full Text] [Related]

  • 8. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.
    Respir Care; 2014 Mar 24; 59(3):388-98. PubMed ID: 23983274
    [Abstract] [Full Text] [Related]

  • 9. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG, Gembitskaia TE.
    Ter Arkh; 2010 Mar 24; 82(8):76-8. PubMed ID: 20873251
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD, Elborn JS.
    Expert Rev Respir Med; 2011 Oct 24; 5(5):609-22. PubMed ID: 21955231
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation.
    Mainz JG, Michl R, Pfister W, Beck JF.
    Am J Respir Crit Care Med; 2011 Nov 01; 184(9):1089-90. PubMed ID: 22045752
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.